SPOTLIGHT: Pfizer HIV drug earns accelerated review

Some much-needed good news from Pfizer: The drug giant announced that its HIV treatment maraviroc will receive accelerated review in both the U.S. and Europe. If approved, maraviroc will be the first in a new class of HIV/AIDS treatments called CCR5 antagonists that work by blocking viral entry. Release